Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

June 30, 2018

Study Completion Date

January 31, 2019

Conditions
Stage IA Pancreatic AdenocarcinomaStage IB Pancreatic AdenocarcinomaStage IIA Pancreatic AdenocarcinomaStage IIB Pancreatic Adenocarcinoma
Interventions
DRUG

nab-paclitaxel

Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

DRUG

gemcitabine

Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

Trial Locations (1)

200032

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Shanghai Pancreatic Cancer Institute; Pancreatic Cancer Institute, Fudan University. Shanghai, China, Shanghai

All Listed Sponsors
lead

Xian-Jun Yu

OTHER

NCT02023021 - Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection | Biotech Hunter | Biotech Hunter